The company’s revenue fell to ¥593.00 million, down from ¥780.00 million in the previous fiscal period. This contraction in top-line growth occurred as the firm continues to navigate the high-cost environment typical of the biotechnology research sector. Despite the lower turnover, Chiome managed to curb its operating loss, which reached ¥979.00 million compared to a ¥1.03 billion loss a year earlier.

Operational Performance and Shareholder Returns

Under Japanese accounting standards, the company’s net loss per share improved to ¥14.47, up from a loss of ¥17.54 in the preceding year. Pretax losses also saw a slight reduction, coming in at ¥989.00 million against the previous ¥1.02 billion, suggesting a stabilization of overhead costs despite the revenue slump.

Chiome Bioscience maintained a cautious stance on capital allocation, reporting zero dividends for the fiscal year. The company confirmed that no payouts were issued for the midyear or year-end periods, and it has not provided dividend forecasts for the upcoming quarters. The results reflect the ongoing financial pressures on the firm as it balances development goals with a tightening revenue stream.